Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
PCRX Transcript
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call shows strong financial performance with growth in sales and improved margins. The company's strategic partnerships, especially with J&J, are poised to boost future growth. The market opportunity for EXPAREL and positive feedback on the pipeline reinforce optimism. Share repurchases signal confidence in undervaluation. Despite some unclear management responses, overall guidance and strategic initiatives support a positive sentiment.
Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings report shows strong financial performance, with record high gross margins and a new partnership with J&J MedTech, enhancing growth prospects. Despite some declines in specific product sales, the overall outlook remains optimistic with raised guidance and shareholder-friendly actions like stock repurchase. The Q&A revealed some management evasiveness, but the positive aspects outweigh these concerns, suggesting a positive stock price movement.
Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with increased EXPAREL sales and improved gross margins. The stock repurchase program signals confidence in future growth, while guidance aligns with strategic goals. Despite concerns in the Q&A about adoption and competition, the optimistic guidance and strategic initiatives suggest a positive outlook. The positive impact of financial metrics and shareholder returns outweighs the uncertainties, leading to a predicted stock price increase of 2% to 8% over the next two weeks.
PCRX Slides
PCRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
